Drug Use Investigation for REVOLADE (ITP)

Novartis

Status: Completed

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Treatments: Drug: Eltrombopag

Study type: Observational

Funder types: Industry

Identifiers

NCT01416311

CETB115B1401 (Other Identifier)

114877

Details and patient eligibility

About

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy.

<Priority investigation item> Thromboembolism

Enrollment: 5,797 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with chronic idiopathic thrombocytopenic purpura

Exclusion criteria

• Not applicable

Trial design

5,797 participants in 1 patient group

Subjects prescribed REVOLADE

Description:

Subjects with chronic idiopathic thrombocytopenic purpura prescribed REVOLADE during study period

Treatment:

Drug: Eltrombopag